Gilead and Kite Oncology Present Important Data Across Multiple Difficult-to-Treat Cancers at ESMO Congress 2023
October 16, 2023 – Pharmaceutical – ESMO Congress 2023, Gilead Sciences, Kite Pharma
– Real-World Evidence and New Clinical Analysis Support the Role of Trodelvy (sacituzumab govitecan-hziy) in Metastatic Breast Cancers
– New Data Demonstrate Potential of Sacituzumab Govitecan in Small Cell Lung Cancer, Urothelial Cancer and Head and Neck Cancers
– Two Analyses Estimate Treatment Effects of Yescarta (axicabtagene ciloleucel) Versus Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
16 October 2023 — Stockley Park, UK — Gilead Sciences and Kite, a Gilead Company, will present new data, including three oral presentations, at the European Society for Medical Oncology (ESMO) Congress 2023. New clinical data for Trodelvy (sacituzumab govitecan-hziy) continue to support its use in metastatic triple-negative breast cancer (mTNBC) and pre-treated HR+/HER2- metastatic breast cancer (mBC) and demonstrates the expanding body of evidence for sacituzumab govitecan in small cell lung cancer and head and neck cancer. Kite will also present analyses supporting the use of Yescarta (axicabtagene ciloleucel) in relapsed/refractory (R/R) diffuse large B-Cell lymphoma (DLBCL).
“Our data at ESMO 2023 reflect a broad clinical development programme in difficult-to-treat cancers,” said Bill Grossman, MD PhD, senior vice president of Therapeutic Area Head at Gilead Oncology. “Sacituzumab govitecan has the potential to impact many patients with cancer across multiple indications, as demonstrated by presentations featuring new data in extensive-stage small cell lung cancer, metastatic urothelial cancer and previously treated head and neck cancer, along with new analyses in metastatic breast cancer.”
Data for sacituzumab govitecan across a range of difficult-to-treat solid tumours, include real-world data that reinforce sacituzumab govitecan as a standard-of-care option in second-line metastatic TNBC and new post-hoc efficacy analyses from the phase 3 TROPiCS-02 study in pre-treated HR+/HER2- metastatic breast cancer. Two mini-oral presentations from the TROPiCS-03 basket trial also support the potential of sacituzumab govitecan in extensive-stage small cell lung cancer (ES-SCLC) and advanced head and neck squamous cell carcinoma (HNSCC). Preliminary findings from a clinical collaboration with Dana Farber Cancer Institute in 2L metastatic urothelial cancer, demonstrated for the first time in any tumour, that potentially two ADCs can be given in combination together.
Comparative analyses of axicabtagene ciloleucel versus bispecific antibodies
In two separate analyses, a Matching-Adjusted Indirect Comparison (MAIC) was conducted of axicabtagene ciloleucel versus glofitamab and epcoritamab, respectively, using published evidence from clinical studies of R/R DLBCL patients treated after at least two prior systemic therapies. Data from the pivotal axicabtagene ciloleucel study (ZUMA-1) were matched to baseline characteristics of glofitamab and epcoritamab studies, respectively, representing clinically relevant prognostic factors (including disease stage, number of prior lines of therapy, ECOG performance status).
“Patients with aggressive relapsed/refractory large B-cell lymphoma face a poor prognosis and have limited options for successful curative therapy,” said Frank Neumann, MD PhD, senior vice president of Global Head of Clinical Development at Kite. “We believe our data will help further clinicians’ understanding of when to use axicabtagene ciloleucel in these patients and reinforce confidence in CAR T-cell therapies overall.”
About Kite
Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, US focused on cell therapy to treat and potentially cure cancer. As the global cell therapy leader, Kite has treated more patients with CAR T-cell therapy than any other company. Kite has the largest in-house cell therapy manufacturing network in the world, spanning process development, vector manufacturing, clinical trial supply and commercial product manufacturing. Visit: www.kitepharma.com.
About Gilead Sciences
Gilead Sciences, Inc is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19 and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California, US. Visit: www.gilead.com.
